Table 2.
Comparative patterns of recurrence by baseline characteristics
| Anterior recurrence (n = 11) | Pectoralis recurrence (n = 6) | P-value | |
|---|---|---|---|
| Laterality | 0.39 | ||
| Left | 7 (64%) | 5 (83%) | |
| Right | 4 (36%) | 1 (17%) | |
| Histology | 0.36 | ||
| Invasive ductal carcinoma | 7 (64%) | 5 (83%) | |
| Invasive lobular carcinoma | 1 (9%) | 1 (17%) | |
| Inflammatory | 3 (27%) | 0 (0%) | |
| Age, years | 0.63 | ||
| <57 | 6 (55%) | 4 (67%) | |
| ≥58 | 5 (46%) | 2 (33%) | |
| Initial disease stage (n = 15) | 0.39 | ||
| I | 0 (0%) | 1 (17%) | |
| II | 4 (44%) | 3 (50%) | |
| III | 5 (56%) | 2 (33%) | |
| Subtype (n = 15) | 0.70 | ||
| ER + PR + HER2- | 5 (50%) | 3 (60%) | |
| ER + PR + HER2 + | 0 (0%) | 0 (0%) | |
| ER-PR-HER2 + | 1 (10%) | 1 (20%) | |
| ER-PR-HER2- | 4 (40%) | 1 (20%) | |
| Prior irradiation (n = 12) | 0.16 | ||
| No | 5 (56%) | 3 (100%) | |
| Yes | 4 (44%) | 0 (0%) |
Abbreviations: ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor.